文献速递血栓与止血

新型人源化抗糖蛋白Ibα抗原结合片段在小鼠血栓性血小板减少性紫癜模型中的预防和治疗作用

Preventative and therapeutic effects of a novel humanized anti-glycoprotein Ibα fragment of antigen-binding region in a murine model of thrombotic thrombocytopenic purpura.
PubMed 文献 · J Thromb Haemost · 2025-02-15

本研究在小鼠模型中评估新型人源化抗血小板糖蛋白Ibα抗体片段CA1001对血栓性血小板减少性紫癜(TTP)的疗效。CA1001剂量和时间依赖性抑制血小板凝集,显著抑制剪切依赖性血小板黏附与聚集,并在组蛋白诱导的Adamts-13缺失小鼠「TTP样」综合征中减轻血小板减少、肾前性损伤和微血管血栓形成。作者认为CA1001可能成为免疫介导性和遗传性TTP的潜在候选治疗药物。

要点

  • CA1001剂量和时间依赖性抑制Botrocetin诱导的小鼠血小板凝集。
  • CA1001显著抑制Adamts-13缺失小鼠剪切依赖性血小板黏附与聚集。
  • CA1001在组蛋白诱导的「TTP样」综合征中减轻血小板减少和微血管血栓形成。

核心结论

  • CA1001能有效抑制VWF-血小板相互作用及多种(病理)生理条件下的血栓形成。
  • CA1001可能成为进一步开发为免疫介导性和遗传性TTP新型治疗药物的潜在候选,或许也适用于其他炎症性血栓性疾病如缺血性卒中。

研究设计与样本

  • 研究采用小鼠TTP模型,运用血小板凝集谱、微流控剪切实验、活体显微镜血栓模型和赖氨酸组蛋白诱导的小鼠「TTP样」模型进行评估。

主要发现

  • CA1001以剂量和时间依赖性方式强效抑制Botrocetin诱导的小鼠血小板凝集。
  • CA1001显著抑制Adamts-13缺失小鼠中剪切依赖性血小板对钙离子载体激活的提睾肌微静脉所释放内皮VWF的黏附和聚集,并阻断富含血小板-VWF血栓的形成。
  • CA1001在Adamts-13缺失小鼠中似乎能有效预防和治疗组蛋白诱导的「TTP样」综合征,表现为血小板减少、肾前性损伤和主要器官组织微血管血栓形成的减轻。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is a potentially fatal blood disorder resulting from severe deficiency of plasma ADAMTS-13 activity. Current treatment for immune-mediated TTP includes daily therapeutic plasma exchange plus caplacizumab and immunosuppressives. For hereditary TTP resulting from mutations of ADAMTS-13, plasma infusion or recombinant ADAMTS-13 is the treatment of choice. However, there are still unmet needs for an effective alternative therapy for TTP. OBJECTIVES: The present study aimed to evaluate the therapeutic efficacy of a novel humanized antibody fragment of antigen binding against platelet glycoprotein Ibα (CA1001) in a murine model of TTP. METHODS: Platelet agglutination profiles, microfluidic shear-based assay, intravital microscopy thrombosis model, and lysine histone-induced murine "TTP-like" model were employed. RESULTS: CA1001 exhibited potent inhibition of botrocetin-induced murine platelet agglutination in a dose- and time-dependent manner. CA1001 also significantly inhibited shear-dependent adhesion and aggregation of murine platelets to endothelial von Willebrand factor (VWF) released from calcium ionophore-activated cremaster venules in Adamts-13 null mice and blocked the formation of platelet-VWF rich thrombosis. More importantly, CA1001 appeared to be efficacious in preventing and treating a histone-induced "TTP-like" syndrome in Adamts-13 null mice, demonstrated by the alleviation of thrombocytopenia, prerenal injury, and formation of microvascular thrombosis in major organ tissues. CONCLUSION: CA1001 can effectively inhibit VWF-platelet interaction and thrombus formation under various (patho)physiological conditions. Thus, CA1001 may be a potential candidate for further development as a novel therapeutic for immune-mediated and hereditary TTP and perhaps for other inflammatory thrombotic disorders such as ischemic stroke.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Zheng L, Adili R, Wu Z, et al. Preventative and therapeutic effects of a novel humanized anti-glycoprotein Ibα fragment of antigen-binding region in a murine model of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2025. PMID: 39956431. doi:10.1016/j.jtha.2025.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。